Background {#Sec1}
==========

Several pharmacological treatments may be considered for type 2 diabetes, but some patients eventually require and benefit from insulin treatment \[[@CR1]\]. Basal insulins are often used in combination with oral hypoglycemic agents or GLP-1 receptor analogs, but rapid-acting insulin analogs (RAIs) may be required to prevent postprandial glucose excursions. Non-inferiority and some clinical advantages over ordinary human insulin (fewer doses, increased flexibility, less hypoglycemia and improved cost-effectiveness) have been documented \[[@CR2]\], but only a few studies have directly compared the clinical efficacy of various RAIs \[[@CR3]--[@CR6]\], and none have addressed long-term cardiovascular safety.

We recently performed a population-based longitudinal cohort study among individuals with type 1 diabetes to address cardiovascular safety and mortality among continuous users of the currently available RAIs (lispro, aspart and glulisine insulins) \[[@CR7]\]. There were no pronounced differences in effectiveness or long-term safety between the three options, although severe hypoglycemia was more common among older patients, while severe hypoglycemia and hyperglycemia were more common among patients with impaired renal function. In a manner that similarly linked data from the Swedish National Diabetes Register (NDR) with other databases to capture information about hospitalization and cause of death, the present study examined long-term, real-life safety data concerning the impact of RAIs among individuals with type 2 diabetes, including elderly patients and those with renal impairment.

Methods {#Sec2}
=======

The regional ethical review board approved this study, which was carried out in accordance with the Declaration of Helsinki. All patients had given informed consent to participation.

Databases {#Sec3}
---------

We used data from several national sources. NDR is a quality registry with nationwide coverage \[[@CR8]\], to which clinical characteristics, treatments and complications are reported annually by hospitals and primary healthcare centers. The Prescribed Drug Register (PDR) covers all prescriptions filled at pharmacies, while the Cause of Death Register contains data about mortality and date of death, while the National Patient Register focuses on hospitalization, procedures and diagnoses (Swedish National Board of Health and Welfare). The Longitudinal Integration Database for Health Insurance and Labor Market Studies is a source for place of birth and educational level. These databases have recently been reviewed and validated \[[@CR9]\].

Patients, study period, follow-up and censoring {#Sec4}
-----------------------------------------------

We identified all persons who had filled prescriptions of RAI, and thereafter included in this study patients with type 2 diabetes (clinical diagnosis as determined by the reporting physician) who were at least 18 years old. The study period was from July 1, 2005 (start date of PDR) to December 31, 2014. The first RAI prescription filled in the PDR after July 1 2005 was defined as the index date. Only patients not previously treated with RAIs (from July 1, 2005 to the index date) but who had used RAIs continuously for at least 1 year after the index date, were included in the study (Fig. [1](#Fig1){ref-type="fig"}). Previously filled prescriptions of a basal insulin were allowed. We defined continuous use as having filled at least three ordinary or 19 multidose (ApoDos) prescriptions during the subsequent 12 months. Patients were monitored the entire study period or until the occurrence of a censoring event. The start of the follow-up period was defined as the date that the third insulin prescription was filled. We used the following censoring events: picking up a new type of RAI, death, emigration to another country or the occurrence of a safety outcome.Fig. 1Patient selection flowchart. Data from the national pharmacy register. NDR, National Diabetes Register. O.P. ordinary prescription, A.P. ApoDos prescription

Patient characteristics {#Sec5}
-----------------------

Baseline (index date) variables included age, gender, duration of diabetes, smoking, physical inactivity (exercising less than once a week), higher (postsecondary) education, history of hyperglycemia or hypoglycemia, history of cardiovascular disease (CVD), glucose-, lipid- and blood pressure-lowering medications, platelet aggregation inhibitors and anticoagulants, as well as type of basal insulin. We used the latest values for HbA1c, BMI, weight, blood pressure, blood lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), and estimated glomerular filtration rate (eGFR) up to 12 months before the index date. The eGFR was calculated using the Modification of Diet in Renal Disease study equation \[[@CR10]\], and renal impairment was defined as eGFR \<60 mL/min/1.73m^2^. HbA1c analyses and other laboratory tests were performed locally.

We defined a history of coronary heart disease (CHD) as diagnosis of ischemic heart disease (I20--I25) or treatment with percutaneous coronary intervention or coronary artery bypass graft prior to the index date (Table [1](#Tab1){ref-type="table"}). Similarly, history of cardiovascular disease (CVD) was defined as diagnosis of stroke or peripheral vascular disease prior to the index date or history of CHD. We used ICD-codes to determine a history of atrial fibrillation, congestive heart failure, stroke, kidney failure, severe hyperglycemia and hypoglycemia.Table 1ICD groups and corresponding codesGroup number and nameICD diagnosis or treatment codes0. Ischemic heart diseaseI20--251. PCIFNG0, FNG00, FNG02, FNG05, FNG06, FNG10, FNG30, FNG962. CABGFNA0, FNA00, FNA10, FNA20, FNA96, FNB00, FNB20, FNB96, FNC10, FNC20, FNC30, FNC40, FNC50, FNC60, FNC96, FND10, FND20, FND96, FNE00, FNE10, FNE20, FNE96, FNF00, FNF10, FNF20, FNF30, FNF963. StrokeI61, I63, I64, I67.94. Peripheral vascular diseaseI70.2, I73.1, I73.9, I79.2, E10.5, E11.5, E14.5. NHQ09, NHQ11, NGQ09, NGQ11, NGQ99, NFQ09, NFQ19, NFQ99, NEQ19, NEQ995. Atrial fibrillationI46--486. Congestive heart failureI507. Kidney failureN18, N198. HypoglycaemiaE100, E106A, E110, E110C, E110X, E116A, E120, E130, E140, E159, E160, E161W, E162, R4029. HyperglycaemiaE100A, E100B, E100D, E100X, E101, E101A, E101B, E101D, E101X, E110, E110A, E110B, E110D, E110X, E111, E111A, E111B, E111D, E111X, R739A. CHD = groups 0--2B. CVD = groups 0--4

Outcomes {#Sec6}
--------

We followed the annual changes in HbA1c and weight, as well as the occurrence of safety outcomes (hospitalization due to hyperglycemia or hypoglycemia, renal failure, cardiovascular events -- CHD, CVD, stroke, atrial fibrillation or congestive heart failure -- or death), according to Table [1](#Tab1){ref-type="table"}.

Statistical methods {#Sec7}
-------------------

Missing baseline data were imputed using multiple changed equations, creating ten data sets \[[@CR11]\]. The percentage of missing data ranged from zero (age, gender, treatment and prior conditions) to 76% (physical activity).

We used a multinomial generalized boosted regression model \[[@CR12]\] with a logistic link function to estimate propensity scores \[[@CR13]\] based on all baseline characteristics and risk factor treatments for each imputed data set. The inverse probability of the given treatment was used to weight differences in baseline characteristics between treatment groups.

Patient characteristics at baseline were summarized by means of standard descriptive statistics. Variations between the treatment groups were evaluated graphically based on the maximal pairwise standardized difference. Unadjusted mean HbA1c and weights were plotted by means of penalized B-splines with 95% confidence intervals (CI). The treatment groups were compared with respect to cardiovascular events and mortality using a weighted Cox proportional hazards model with robust standard errors that reflected the weighted analysis \[[@CR14]\]. We used SAS version 9.4 and R version 3.1.0 to perform the statistical calculations.

Results {#Sec8}
=======

We followed 17,620 patients with type 2 diabetes who used RAIs continuously for up to 6.4 years. There were numerical differences in baseline characteristics between the treatment groups before inverse probability of treatment weighting (Table [2](#Tab2){ref-type="table"}). Prior to weighting only age and duration differed between treatments with a maximal pairwise standardized difference (SD) of 10.2 and 11.5%, respectively. After the weights were applied, the SD decreased to less than 2.4%, demonstrating perfect balance between the three treatment groups. Overall, around 40% were female and the mean age was slightly higher than 60, 41.9--49.2% of the patients being age 65 or older, and diabetes duration between 9.9 and 11.7 years. The mean BMI was 30.5 kg/m^2^, HbA1c around 70 mmol/mol (8.6% National Glycohemoglobin Standardization Program), total cholesterol 4.7 mmol/l, serum triglycerides 2.2 mmol/l and HDL cholesterol 1.2 mmol/l, while mean blood pressure was around 135/76 mmHg. Mean serum creatinine was around 84, eGFR 82 ml/min/1.73 m^2^, with between 40.9% and 54.0% of the patients exhibiting eGFR \<60 ml/min/1.73 m^2^. There were small differences in the percentage of smokers, physical inactivity and education level, as well as in use of oral hypoglycemic agents, GLP-1 receptor agonists and lipid-lowering medication. Around 95% of the patients also used another type of insulin, but only 12 patients used insulin pumps (five lispro, six aspart, one glulisine). A history of cardiovascular disease was common and similar in the three treatment groups (24.2--24.7%), as was the case with atrial fibrillation and congestive heart failure (CHF), while the proportion of patients who had been hospitalized due to severe hypoglycemia or hyperglycemia was only 2.0--3.6% (Table [2](#Tab2){ref-type="table"}).Table 2Baseline characteristics of patients treated with lispro, aspart and glulisineLispro\
(*n* = 1986)Aspart\
(*n* = 14,501)Glulisine (*n* = 1133)Age, years (SD)60.8 (12.9)60.9 (12.4)63.2 (10.8)Age 65 years or older, n (%)1861 (43.4%)6082 (41.9%)558 (49.2%)Female, n (%)796 (40.1)5460 (37.7)445 (39.3)Diabetes duration, years (SD)10.8 (8.2)9.9 (8.1)11.7 (7.6)Total cholesterol, mmol/L (SD)4.7 (1.1)4.7 (1.1)4.6 (1.1)Triglycerides, mmol/L (SD)2.2 (1.5)2.2 (1.5)2.2 (1.7)HDL, mmol/L (SD)1.2 (0.4)1.2 (0.4)1.2 (0.4)HbA1c, mmol/mol (SD)70.9 (17.0)69.6 (16.6)70.4 (16.6)BMI, kg/m^2^ (SD)30.5 (4.9)30.5 (4.9)30.6 (5.1)Systolic BP, mmHg (SD)134.6 (15.7)136.0 (16.7)135.8 (15.7)Diastolic BP, mmHg (SD)76.7 (9.7)76.9 (9.8)76.1 (9.9)Serum creatinine, x (SD)82.7 (33.8)84.6 (38.4)83.9 (32.7)eGFR, mL/min/1.73m^2^ (SD)83.5 (36.2)82.3 (29.1)81.5 (27.7)Renal impairment, n (%)911 (45.9%)5924 (40.9%)612 (54.0%)Smokers, n (%)164 (14.1%)1176 (15.5%)101 (12.8%)Higher education, n (%)405 (20.7%)2531 (17.7%)206 (18.5%)Physical inactivity, n (%)307 (30.8%)2052 (31.7%)196 (28.7%)Oral hypoglycemic agent, n (%) Metformin1433 (72.2%)9805 (67.6%)865 (76.3%) Sulphonylurea/meglitinide672 (33.8%)5316 (36.7%)514 (45.4)) Thiazolidindione97 (4.9%)822 (5.7%)87 (7.7%) DPP-4 inhibitor149 (7.5%)656 (4.5%)102 (9.0%) Acarbose27 (1.4%)201 (1.4%)22 (1.9%)GLP-1 receptor agonist104 (5.2%)324 (2.2%)63 (5.6%)Insulin pump (CSII), n (%)5 (0.6%)6 (0.1%)1 (0.2%)Other insulin, n (%)1865 (93.9%)13,780 (95.0%)1090 (96.2%)Lipid-lowering agent, n (%)1282 (64.6%)9149 (63.1%)841 (74,2%)History of ..., n (%) Ischemic heart disease204 (12.1%)1561 (10.8%)123 (10.9%) Atrial fibrillation167 (8.4%)1306 (9.0%)82 (7.2%) Myocardial infarction182 (9.2%)1344 (9.3%)108 (9.5%) Unstable angina298 (15.0%)2032 (14.0%)163 (14.4%) PCI176 (8.9%)1145 (7.9%)83 (7.3%) CABG95 (4.8%)750 (5.2%)52 (4.6%) Peripheral vascular disease41 (2.1%)469 (3.2%)27 (2.4%) Stroke106 (5.3%)693 (4.8%)44 (3.9%) Congestive heart failure158 (8.0%)1187 (8.2%)71 (6.3%) Hypoglycaemia39 (2.0%)306 (2.1%)24 (2.1%) Hyperglycaemia64 (3.2%)516 (3.6%)30 (2.6%)Means, standard deviations (SD), proportions; BP, blood pressure

The mean follow-up periods were 2.0, 2.9 and 1.9 years among patients treated with insulins lispro, aspart and glulisine, respectively. Unadjusted mean HbA1c and weight during the follow-up period were stable and very similar (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). The absolute numbers and incidence rates of death, cardiovascular events, CHF, renal failure and severe hypoglycemia or hyperglycemia are shown in Table [3](#Tab3){ref-type="table"}. The incidence rates of death were 234.4, 284.9 and 156.7 per 1000 person-years among users of lispro, aspart, and glulisine, respectively, while the incidence rates of all cardiovascular events were 668.4, 622.4, and 699.5 per 1000 person-years, respectively.Fig. 2Average HbA1c during follow-up period among patients treated with lispro, aspart, and glulisine Fig. 3Average weight during follow-up period among patients treated with lispro, aspart, and glulisine Table 3Follow-up period, number of events and incidence per 1000 person-yearsEventLispro(*n* = 1986)Aspart(*n* = 14,501)Glulisine(*n* = 1133)Deaths93 (234.4)1192 (284.9)33 (156.7)Fatal CHD29 (73.1)352 (84.1)13 (61.7)Fatal CVD34 (85.7)424 (101.3)14 (66.5)CHD196 (546.9)1896 (489.9)110 (571.9)CVD234 (668.4)2312 (622.4)132 (699.5)Stroke39 (99.7)412 (100.1)11 (52.6)Heart failure109 (289.0)1177 (295.5)46 (225.7)Kidney failure75 (193.8)708 (173.4)28 (135.8)Hypoglycemia15 (38.1)234 (56.5)12 (57.6)Hyperglycemia10 (25.3)190 (45.8)7 (33.4)Maximum follow up time, years6.36.46.1Mean follow up time, years2.02.91.9Median follow up time, years1.32.91.8Number of events (incidence per 1000 person-years). CHD coronary heart disease, CVD cardiovascular disease

We used Cox regression analyses to distinguish differences among the treatment groups with respect to mortality, CVD, CHF, renal failure and risk of hypoglycemia or hyperglycemia that required hospitalization (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). There were no statistically significant differences, apart from a lower relative mortality risk among patients on insulin glulisine than on insulin aspart, lower risks of stroke among users of glulisine, and higher risk of severe hyperglycemia among aspart than lispro users. For patients age 65 or older, these results were virtually unchanged, but users of lispro were also at lower risk of severe hypoglycemia. Among patients with renal impairment (Table [6](#Tab6){ref-type="table"}), there were no significant differences between the treatment groups.Table 4Risks of death and hospitalisationsEventAspart vs lisproGlulisine vs lisproGlulisine vs aspartTotal Mortality1.23 \[0.98, 1.53\]0.65 \[0.41, 1.53\]0.53 \[0.35, 0.8\]\*CHD0.96 \[0.82, 1.12\]1.03 \[0.79, 1.36\]1.08 \[0.85, 1.35\]Fatal CHD1.17 \[0.79, 1.74\]1.04 \[0.50, 2.16\]0.89 \[0.47, 1.67\]CVD0.95 \[0.82, 1.09\]1.03 \[0.80, 1.31\]1.08 \[0.88, 1.33\]Fatal CVD1.15 \[0.80, 1.66\]0.88 \[0.44, 1.78\]0.77 \[0.41, 1.42\]Stroke0.94 \[0.67, 1.34\]0.33 \[0.16, 0.66\]\*0.34 \[0.18, 0.65\]\*Heart Failure1.00 \[0.82, 1.23\]0.76 \[0.50, 1.13\]0.75 \[0.53, 1.08\]Kidney Failure0.88 \[0.68, 1.13\]0.71 \[0.42, 1.20\]0.81 \[0.50, 1.30\]Hypoglycaemia1.42 \[0.83, 2.44\]1.30 \[0.55, 3.10\]0.92 \[0.45, 1.85\]Hyperglycaemia1.97 \[1.01, 3.85\]\*1.88 \[0.66, 5.33\]0.96 \[0.42, 2.18\]Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. \* *p*-value \<0.05 Table 5Risks of death and hospitalisations: subgroup analysis in patients 65 years or olderEventAspart vs lisproGlulisine vs lisproGlulisine vs aspartTotal Mortality1.10 \[0.84, 1.44\]0.61 \[0.37, 1.02\]0.56 \[0.36, 0.87\]CHD1.02 \[0.83, 1.26\]1.09 \[0.78, 1.52\]1.06 \[0.81, 1.40\]Fatal CHD1.18 \[0.74, 1.89\]0.85 \[0.38, 1.90\]0.72 \[0.37, 1.40\]CVD0.95 \[0.78, 1.14\]0.98 \[0.72, 1.33\]1.04 \[0.80, 1.34\]Fatal CVD1.15 \[0.75, 1.78\]0.76 \[0.36, 1.61\]0.66 \[0.35, 1.23\]Stroke0.86 \[0.56, 1.33\]0.28 \[0.11, 0.71\]\*0.32 \[0.14, 0.76\]\*Heart Failure0.97 \[0.75, 1.25\]0.74 \[0.47, 1.18\]0.77 \[0.51, 1.15\]Kidney Failure0.78 \[0.58, 1.06\]0.68 \[0.38, 1.22\]0.87 \[0.52, 1.46\]Hypoglycaemia2.37 \[1.07, 5.25\]\*3.24 \[1.12, 9.42\]\*1.37 \[0.65, 2.88\]Hyperglycaemia4.67 \[1.49, 14.65\]\*0.39 \[0.09, 1.64\]0.39 \[0.09, 1.64\]Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. \* *p*-value \<0.05 Table 6Risks of death and hospitalisations: subgroup analysis in patients with renal impairmentEventAspart vs lisproGlulisine vs lisproGlulisine vs aspartTotal Mortality0.97 \[0.61, 1.54\]0.56 \[0.21, 1.50\]0.58 \[0.24, 1.40\]CHD1.05 \[0.70, 1.60\]0.96 \[0.51, 1.81\]0.91 \[0.55, 1.50\]Fatal CHD1.17 \[0.79, 1.74\]1.04 \[0.50, 2.16\]0.89 \[0.47, 1.67\]CVD1.12 \[0.76, 1.66\]1.00 \[0.56, 1.80\]0.89 \[0.56, 1.41\]Fatal CVD1.47 \[0.67, 3.26\]0.68 \[0.12, 3.84\]0.46 \[0.10, 2.19\]Stroke1.32 \[0.50, 3.51\]0.64 \[0.12, 3.34\]0.49 \[0.12, 2.06\]Heart Failure1.03 \[0.65, 1.64\]0.65 \[0.28, 1.52\]0.63 \[0.30, 1.31\]Kidney Failure1.20 \[0.76, 1.88\]0.98 \[0.47, 2.03\]0.82 \[0.45, 1.48\]Hypoglycaemia1.46 \[0.45, 4.72\]1.33 \[0.22, 8.20\]0.91 \[0.22, 3.82\]Hyperglycaemia3.32 \[0.46, 24.19\]N/AN/AWeighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. \* *p*-value \<0.05

Discussion {#Sec9}
==========

This observational study of 17,620 patients with type 2 diabetes monitored for up to 6.4 years provides information about the long-term effectiveness and safety of RAIs. The impact on weight and glycemic control was very similar between the three RAI groups. Overall, there were no differences in the risks of mortality or hospitalization due to CVD, CHF or renal failure using weighted Cox proportional hazards models, particularly among patients with impaired renal function. There seems, however, to be a significantly lower relative mortality risk among patients on insulin glulisine than on insulin aspart, as well as lower risk of stroke among users of glulisine in the total cohort and age 65 or older. Similarly, the risk of severe hyperglycemia was higher among lispro than aspart users, as well as of severe hypoglycemia than among both aspart and glulisine users in the older age group. The results are generally consistent with our previous report of type 1 diabetes \[[@CR7]\] but for a larger group of patients with type 2 diabetes, who are at higher cardiovascular risk.

The results suggest a beneficial effect of insulin glulisine on overall mortality and stroke, but there were no differences in terms of fatal CHD or CVD between any of the groups. It is highly unlikely that other mechanisms would cause such an effect, such as, e.g., differences in pharmacokinetic or pharmacodynamics profiles, vascular effects or mitogenic activity \[[@CR2], [@CR7]\]. As in most observational studies, residual confounding is likely to be a contributing factor. Nevertheless, the major strengths of this study are its nationwide scope and statistical methods, which take all available clinical characteristics and treatment options into consideration.

The interpretation of the results is complicated by the effects of other risk factors and treatments, such as the use of antihypertensive, antihyperlipidemic or glucose-lowering agents, all of which can change with time. We did, however, take all baseline characteristics and risk factor treatments into account in the weighted Cox regression analyses. Given that the patients are encouraged to frequently adjust the dosage of the various insulin injections on their own during the follow-up period, we have not analyzed the possible role of dose size. Moreover, almost all patients used basal insulin. We did, however, only include patients not previously treated with RAI in order to rule out the effect of previous use of various insulin preparations that had been marketed on different dates.

Current glucose-lowering treatments, such as SGLT-2 inhibitors, DPP-4 inhibitors and GLP-1 receptor analogs, have been examined with regard to long-term safety in major randomized clinical outcome trials \[[@CR15]--[@CR17]\]. The ORIGIN trial showed that insulin glargine is non-inferior to other pharmacological treatments with respect to cardiovascular outcomes, cancer and death in individuals with type 2 diabetes and high cardiovascular risk \[[@CR18]\]. But data are not yet available from any additional prospective studies concerning the long-term safety of other types of insulin. Post-marketing surveillance and observational cohort studies are needed to monitor the effects of older treatments in clinical practice. Such studies can provide data quality comparable to that of randomized control trials, which are usually limited by poor external validity \[[@CR19]\].

Conclusion {#Sec10}
==========

Our conclusion is that there do not appear to have been any major clinically important differences in effects on hypoglycemia, hyperglycemia, weight or long-term safety between the three available RAIs among insulin-naive individuals with type 2 diabetes who were monitored for up to 6.4 years in clinical practice.
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